Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 24:16:849-865.
doi: 10.2147/OTT.S425523. eCollection 2023.

HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies

Yunhe Xie  1   2 , Jiarong Ye  3 , Hongliang Luo  1
Affiliations
Review

HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies

Yunhe Xie et al. Onco Targets Ther. .

Abstract

HOXC cluster antisense RNA 3 (HOXC-AS3) is a novel long noncoding RNA (lncRNA) that exhibits aberrant expression patterns in various cancer types. Its expression is closely related to clinicopathological features, demonstrating significant clinical relevance across multiple tumors. And HOXC-AS3 plays multifaceted roles in tumor progression, impacting cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), autophagy, senescence, tumor growth, and metastasis. In this review, we summarized and comprehensively analyzed the expression and clinical significance of HOXC-AS3 as a diagnostic and prognostic biomarker for malignancies. Additionally, we presented an in-depth update on HOXC-AS3's functions and regulatory mechanisms in cancer pathogenesis. This narrative review underscores the importance of HOXC-AS3 as a promising lncRNA candidate in cancer research and its potential as a predictive biomarker and therapeutic target in clinical applications.

Keywords: HOXC-AS3; biological marker; long non-coding RNA; malignant neoplasms; neoplastic processes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Optimal secondary structure of lncRNA HOXC-AS3. (A) sequence and dot-bracket notation, colored by base-pairing probability. (B) minimum free energy secondary structure of lncRNA HOXC-AS3, colored by base-pairing probability.
Figure 2
Figure 2
Expression of HOXC-AS3 across diverse normal human tissues was shown in violin plots (A) and cluster heatmaps (B) from GTEx.
Figure 3
Figure 3
The expression level of HOXC-AS3 in different cancers from digestive and respiratory systems (A), genitourinary and gynecologic (B), and other systems (C) from UCSC Xena datasets.
Figure 4
Figure 4
The relationship between HOXC-AS3 expression and OS/DSS/PFI in different cancers from TCGA (A) and KM curves showed the significant prognostic value of HOXC-AS3 overexpression in ACC, GBM, and SKCM (B).
Figure 5
Figure 5
Diagnostic ROC curves of HOXC-AS3 expression for differentiating tumor from normal tissue in pan-cancer (A) using UCSC XENA datasets, and HOXC-AS3 expression showed strong diagnostic value in PCPG, ESCA, SKCM, and TGCT (B).
Figure 6
Figure 6
Main mechanisms of HOXC-AS3 in tumorigenesis and progression. The red “x” represents the inhibition of a specific process, and the blue dashed line signifies the interaction between components.
Figure 7
Figure 7
Regulatory mechanisms of lncRNA HOXC‑AS3 in breast cancer.
Figure 8
Figure 8
Regulatory mechanisms of lncRNA HOXC-AS3 in non-small cell lung cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mattick JS, Amaral PP, Carninci P, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430–447. doi:10.1038/s41580-022-00566-8 - DOI - PMC - PubMed
    1. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 2016;14(1):42–54. doi:10.1016/j.gpb.2015.09.006 - DOI - PMC - PubMed
    1. Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15(1):43. doi:10.1186/s12943-016-0530-6 - DOI - PMC - PubMed
    1. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–669. doi:10.1534/genetics.112.146704 - DOI - PMC - PubMed
    1. Li J, Tian H, Yang J, Gong Z. Long noncoding RNAs regulate cell growth, proliferation, and apoptosis. DNA Cell Biol. 2016;35(9):459–470. doi:10.1089/dna.2015.3187 - DOI - PubMed